initial public offerings (IPOs) trading on American exchanges

Monday, January 5, 2015

Neuroderm (NDRM) began trading on the NASDAQ on 14 November 2014


Neuroderm Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development of treatments for central nervous system (CNS) disorders. It develops product candidates for the treatment of Parkinson’s disease and cognition. The Company’s product pipeline includes ND0612L, for moderate PD; ND0612H, for severe PD; ND0680, for severe PD; ND0701, for severe PD, and ND0801, for Cognitive Disorders. It developed a liquid formulation of levodopa (LD) and carbidopa (CD). The Company developed a line of LD/CD product candidates administered through a patch-pump or small belt pump that deliver a continuous, controlled dose of LD/CD to the blood stream. Its LD/CD line of product candidates includes ND0612L, ND0612H and ND0680. The Company also develops ND0701, a formulation of continuous apomorphine therapy for the treatment of Parkinson’s disease.


3 Pekeris Street, Ruhrberg Science Bldg. Rabin Science Park Bell Entrance
REHOVOT, 7670212

Key stats and ratios

Q2 (Jun '14)2013
Net profit margin--
Operating margin--
EBITD margin--
Return on average assets-245.61%-2977.32%
Return on average equity--

No comments:

Post a Comment